Corticosteroid Ointment Recalled Due to Bacterial Contamination
To date, the Company has not received reports of adverse events related to this recall.
To date, the Company has not received reports of adverse events related to this recall.
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Cancer therapies have benefits beyond simple cosmetic repairs, with significant influence on patient outcomes that improve quality of life in many domains including physical, emotional, and social.
The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD.
The safety and efficacy of ustekinumab was determined in a phase 2 trial for the treatment of recurrent oral ulcers in Behçet disease.
The effects of various therapies for telangiectasias and reticular veins are reviewed.
Author reviews a case of prurigo pigmentosa in a patient following the ketogenic diet and outlines a strategy to diagnose and treat this condition.
A novel study reports the efficacy and safety of upadacitinib and topical corticosteroid through 52 weeks for the treatment of atopic dermatitis.
The efficacy and safety of tralokinumab plus topical corticosteroids in adult patients with inadequately controlled severe atopic dermatitis (AD) is assessed.